HBM1007 / Harbour BioMed - LARVOL DELTA

US FDA Grants Investigational New Drug Clearance to HBM’s Cancer Tumor Treatment (Market Screener) - "The US Food and Drug Administration granted investigational new drug clearance to HBM Holdings...to begin clinical trials in the US of HBM1007 for the treatment of cancer tumors, according to a Thursday filing."

IND • Oncology

Harbour BioMed Announces 2022 Interim Results (PRNewswire) - "HBM9027 is currently in preclinical studies and is expected to be submitted for an IND application in 2023. A number of innovative global programs are expected to file IND by the end of 2022, including HBM1020, HBM1022, and HBM1007."

IND • Oncology

Harbour BioMed Reports 2021 Interim Results (PRNewswire) - "HBM7008: HBM7008 is a bispecific antibody targeting Tumor Associated Antigen (B7H4)x4-1BB...It is expected to file a CTA/IRB submission in the second half of 2021; HBM1007: HBM1007 is a fully human monoclonal antibody against CD73 generated from HBM's H2L2 platform...HBM1007 is being studied in preclinical setting and an IND application is expected to be submitted in 2022."

Clinical • IND • Oncology